[Pe-017] English Poster Session 017「Neurogenetics, Gene therapy, and iPS cell 1」

[Pe-017-4] Establishment of a synucleinopathy iPSC cohort for disease modeling and drug discovery

Hidefumi Suzuki^1,2,3, Naohiro Egawa^1,2,3, Keiko Imamura^2,3,4, Takayuki Kondo^2,3,4, Kayoko Tsukita^2,3, Ayako Nagahashi^2,4, Takako Enami^2,4, Kazuko Hasegawa⁵, Hirofumi Maruyama⁶, Hideyuki Sawada⁷, Tomoko Oeda⁷, Mitsuo Kodama⁸, Tsuyoshi Uchiyama⁹, Ryosuke Takahashi¹, Haruhisa Inoue^2,3,4 (1.Department of Neurology, Kyoto University Graduate School of Medicine, Japan, 2.Center for iPS Cell Research and Application (CiRA), Kyoto University, Japan, 3.iPSC-based Drug Discovery and Development Team, RIKEN BioResource Research Center, Japan, 4.Medical-risk Avoidance based on iPS Cells Team, RIKEN Center for Advanced Intelligence Project (AIP), Japan, 5.Department of Neurology, National Hospital Organization Sagamihara National Hospital, Japan, 6.Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, Japan, 7.Clinical Research Center and Department of Neurology National Hospital Organization Utano Hospital, Japan, 8.Department of Neurology, Koshokai Aobaoka Hospital, Japan, 9.Department of Neurology, Seirei Hamamatsu General Hospital, Japan)